ArticleHemaSphere2020

HOVON110/ReBeL Study: Results of the Phase I Part of a Randomized Phase I/II Study of Lenalidomide, Rituximab With or Without Bendamustine in Patients With Relapsed/Refractory Follicular Lymphoma.

Wendy B C Stevens et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.